Stock listing
NASDAQ:SPRB Spruce Biosciences, Inc. Stock
Home listing (NASDAQ) of Spruce Biosciences, Inc.
Follow Spruce Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SPRB
$38.00 USD -2.84 (-7.0%)
Close on Nov 20, 2026
- Day range
- $38.00 – $40.96 USDNov 20, 2026
- Volume
- 108,276 sharesNov 20, 2026
- Market cap
- $109.2M USDAt the close on Nov 20, 2026 · price × 2.87M shares outstanding
- 52-week range
- $38.00 – $112.26 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.40M USDMedian day 83,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SPRB · Home | $38.00 USD | -2.84 (-7.0%) | 108,276 | $39.97 | $40.96 | $38.00 | $40.84 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SPRB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $38.00 | -2.84 | -7.0% | $39.97 | $40.96 | $38.00 | 108,276 | |
| $40.84 | +0.35 | +0.9% | $41.92 | $41.92 | $39.91 | 63,334 | |
| $40.49 | -1.76 | -4.2% | $41.14 | $41.80 | $39.98 | 152,243 | |
| $42.25 | -1.06 | -2.4% | $45.04 | $45.04 | $41.56 | 102,928 | |
| $43.31 | +0.42 | +1.0% | $42.94 | $43.38 | $41.41 | 38,864 | |
| $42.89 | -3.31 | -7.2% | $46.00 | $46.00 | $42.09 | 46,002 | |
| $46.20 | -0.465 | -1.0% | $47.00 | $47.37 | $45.44 | 50,234 | |
| $46.67 | -2.675 | -5.4% | $48.30 | $48.30 | $44.74 | 72,442 | |
| $49.34 | +2.79 | +6.0% | $45.10 | $51.29 | $41.00 | 136,237 | |
| $46.55 | +3.84 | +9.0% | $42.95 | $46.80 | $42.95 | 63,697 | |
| $42.71 | -3.90 | -8.4% | $46.15 | $46.58 | $42.50 | 56,165 | |
| $46.61 | +3.80 | +8.9% | $44.43 | $46.61 | $44.43 | 51,951 | |
| $42.81 | -1.74 | -3.9% | $45.00 | $45.27 | $42.51 | 73,480 | |
| $44.55 | -1.84 | -4.0% | $46.40 | $46.99 | $43.78 | 90,535 | |
| $46.39 | -0.43 | -0.9% | $46.11 | $46.62 | $44.69 | 65,958 | |
| $46.82 | -0.17 | -0.4% | $47.50 | $49.85 | $46.51 | 104,183 | |
| $46.99 | +1.34 | +2.9% | $45.65 | $47.25 | $45.65 | 58,802 | |
| $45.65 | +1.66 | +3.8% | $44.54 | $46.90 | $44.01 | 91,553 | |
| $43.99 | -1.16 | -2.6% | $45.47 | $45.47 | $43.62 | 66,476 | |
| $45.15 | -0.85 | -1.8% | $45.80 | $46.10 | $43.34 | 73,800 | |
| $46.00 | +3.27 | +7.7% | $42.58 | $46.25 | $42.51 | 126,500 | |
| $42.73 | +1.50 | +3.6% | $41.00 | $42.73 | $40.82 | 61,500 | |
| $41.23 | +0.83 | +2.1% | $40.57 | $42.65 | $40.40 | 52,500 | |
| $40.40 | +0.75 | +1.9% | $39.97 | $41.00 | $39.25 | 57,100 | |
| $39.65 | -1.82 | -4.4% | $41.53 | $41.84 | $39.21 | 88,400 | |
| $41.47 | +2.49 | +6.4% | $39.00 | $41.88 | $39.00 | 63,800 | |
| $38.98 | -1.37 | -3.4% | $40.00 | $41.44 | $38.06 | 112,700 | |
| $40.35 | -2.52 | -5.9% | $42.80 | $42.91 | $40.19 | 110,600 | |
| $42.87 | -1.18 | -2.7% | $44.09 | $44.94 | $42.55 | 74,900 | |
| $44.05 | -1.49 | -3.3% | $44.84 | $45.04 | $42.80 | 83,800 | |
| $45.54 | +1.14 | +2.6% | $43.50 | $45.65 | $43.34 | 50,800 | |
| $44.40 | +1.615 | +3.8% | $42.56 | $45.40 | $42.37 | 59,700 | |
| $42.79 | -2.635 | -5.8% | $45.60 | $46.72 | $42.50 | 101,900 | |
| $45.42 | -0.29 | -0.6% | $45.51 | $46.80 | $43.83 | 65,100 | |
| $45.71 | +0.94 | +2.1% | $46.58 | $47.73 | $44.13 | 77,200 | |
| $44.77 | -3.81 | -7.8% | $48.15 | $49.20 | $44.47 | 79,600 | |
| $48.58 | +1.31 | +2.8% | $47.78 | $49.95 | $47.76 | 61,300 | |
| $47.27 | -0.24 | -0.5% | $47.55 | $48.00 | $46.55 | 84,200 | |
| $47.51 | -1.21 | -2.5% | $48.28 | $48.99 | $47.01 | 42,400 | |
| $48.72 | -0.30 | -0.6% | $49.22 | $49.31 | $47.54 | 37,200 | |
| $49.02 | -0.395 | -0.8% | $49.01 | $49.50 | $47.58 | 85,800 | |
| $49.42 | -0.575 | -1.2% | $50.50 | $50.74 | $45.01 | 174,800 | |
| $49.99 | -3.71 | -6.9% | $54.05 | $54.98 | $49.23 | 140,700 | |
| $53.70 | +0.65 | +1.2% | $53.84 | $55.06 | $53.07 | 96,500 | |
| $53.05 | -0.81 | -1.5% | $53.04 | $53.86 | $51.80 | 99,700 | |
| $53.86 | -0.30 | -0.6% | $56.22 | $57.11 | $53.28 | 135,300 | |
| $54.16 | -1.005 | -1.8% | $55.01 | $56.27 | $53.26 | 96,600 | |
| $55.17 | -1.685 | -3.0% | $55.99 | $56.36 | $54.51 | 105,500 | |
| $56.85 | +3.15 | +5.9% | $53.28 | $57.55 | $52.66 | 102,600 | |
| $53.70 | -0.65 | -1.2% | $54.78 | $56.08 | $53.09 | 88,500 | |
| $54.35 | -1.39 | -2.5% | $55.61 | $57.50 | $54.03 | 113,000 | |
| $55.74 | -3.35 | -5.7% | $58.52 | $59.01 | $55.70 | 91,900 | |
| $59.09 | +1.16 | +2.0% | $57.39 | $60.51 | $56.60 | 193,000 | |
| $57.93 | +0.22 | +0.4% | $57.37 | $58.19 | $56.57 | 103,900 | |
| $57.71 | -1.96 | -3.3% | $59.76 | $60.32 | $57.30 | 113,500 | |
| $59.67 | +4.07 | +7.3% | $56.52 | $60.13 | $56.52 | 268,100 | |
| $55.60 | -3.37 | -5.7% | $58.01 | $58.05 | $55.34 | 58,100 | |
| $58.97 | -1.81 | -3.0% | $60.54 | $60.90 | $57.58 | 44,900 | |
| $60.78 | -2.52 | -4.0% | $62.12 | $62.98 | $59.90 | 40,000 | |
| $63.30 | +1.82 | +3.0% | $62.00 | $63.56 | $60.55 | 80,300 | |
| $61.48 | -1.92 | -3.0% | $64.50 | $64.50 | $60.46 | 91,800 | |
| $63.40 | +4.75 | +8.1% | $58.82 | $64.15 | $58.00 | 147,298 | |
| $58.65 | +7.07 | +13.7% | $53.04 | $58.92 | $51.16 | 138,812 | |
| $51.58 | -0.405 | -0.8% | $52.48 | $53.00 | $49.03 | 62,300 | |
| $51.99 | -0.975 | -1.8% | $52.83 | $52.89 | $50.50 | 21,600 |
Splits
1 split · NASDAQ:SPRB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-75 | Consolidation |
- Ticker
- NASDAQ:SPRB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Latest deck · Aug 12, 2026
Investor Presentation (August 2026)
Investor deck · 22 slides
Latest news
Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Nov 9, 2026
Closed $49.34 (+6.0%) on Nov 9, 2026
Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences
Nov 9, 2026
Closed $49.34 (+6.0%) on Nov 9, 2026
Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 2, 2026
Closed $42.81 (-3.9%) on Nov 3, 2026
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
Oct 15, 2026
Closed $39.65 (-4.4%) on Oct 16, 2026
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
Oct 8, 2026
Closed $44.05 (-3.3%) on Oct 9, 2026
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $55.74 (-5.7%) on Sep 9, 2026
Spruce Biosciences Announces Launch of MPS3BStudy.com
Aug 26, 2026
Closed $61.48 (-3.0%) on Aug 26, 2026
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
Aug 24, 2026
Closed $58.65 (+13.7%) on Aug 24, 2026
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
Aug 12, 2026
Closed $47.07 (+1.4%) on Aug 12, 2026
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
Aug 3, 2026
Closed $43.14 (+0.7%) on Aug 3, 2026
Spruce Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 86 in all · newest Nov 9, 2026 · oldest 2020
- Decks
- 4 decks · latest Aug 12, 2026
Where Spruce Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SPRB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SPRB | BOATS | United States | USD |
Valuation
Price/book 1.6× against a median of 2.0×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $41.00M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 1.73
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Spruce Biosciences, Inc. · NASDAQ:SPRB | US$109.2M | US$41.00M | n/a | n/a | n/a | 1.6× | n/a | 0.3× | 1.73 |
| Sinew Pharma, Inc. · TPEX:6634 | US$114.4M | US$84.23M | n/a | 59,064× | n/a | 3.6× | n/a | 0.0× | n/a |
| Armata Pharmaceuticals, Inc. · AMEX:ARMP | US$112.7M | US$346.0M | n/a | 45.8× | n/a | n/a | n/a | n/a | 0.97 |
| Medigen Biotechnology Corporation · TPEX:3176 | US$111.8M | US$61.95M | n/a | 1.6× | n/a | 2.5× | −19.9% | 0.8× | n/a |
| Fate Therapeutics, Inc. · NASDAQ:FATE | US$111.7M | US$47.08M | n/a | 9.9× | n/a | 0.8× | n/a | 0.6× | 2.25 |
| OnKure Therapeutics, Inc. · NASDAQ:OKUR | US$109.4M | −US$53.16M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.17 |
| NIBEC Co., Ltd. · KRX:138610 | US$108.7M | US$92.50M | n/a | 5.5× | 118× | 3.0× | −0.1% | 0.0× | n/a |
| Jyong Biotech Ltd. · NASDAQ:MENS | US$107.6M | US$125.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.74 |
| Nykode Therapeutics ASA · OSL:NYKD | US$107.0M | US$62.24M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126 | US$105.3M | US$84.72M | n/a | 2.0× | n/a | 1.6× | −195.8% | 0.6× | n/a |
| Genelux Corporation · NASDAQ:GNLX | US$104.3M | US$93.85M | n/a | 11,732× | n/a | 11.4× | n/a | 0.0× | 1.52 |
| Median of the others | US$109.0M | US$84.47M | 9.9× | 118× | 2.0× | −19.9% | 0.0× | 1.52 |
Forecasts
8 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 147.89 USD · Analysts' mean
- EPS, year to Dec 2026
- -25.80 · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Javier Szwarcberg | Chief Executive Officer |
| Samir Gharib | President and Chief Financial Officer |
| Tina Gullotta | Vice President, Finance and Corporate Controller |
| Agnieszka AJ Jurecka | Vice President, Medical Affairs |
| Brian Walls | Vice President, Market Access |
| Bruno Gagnon | Senior Vice President, Clinical Development Operations |
| Darren Johnson | Vice President, Commercial Operations |
| Dash Reddy | Vice President, Pharmaceutical Development and Manufacturing |
| Daven Mody | Senior Vice President, Regulatory and Quality |
| Eric Jordan | Vice President, Marketing |
| Jessica Cohen Pfeffer | Vice President, Clinical Development |
| Saba Sile | Senior Vice President, Clinical Development |
| Adrian Quartel | Chief Medical Officer |
| Dale Hooks | Chief Commercial Officer |
| Michael Grey | Executive Chairman |
Board
| Director | Role |
|---|---|
| Michael Grey | Executive Chairman |
| Camilla V. Simpson | Independent |
| Dan Spiegelman | Independent |
| Javier Szwarcberg | Chief Executive Officer |
| Keli Walbert | Independent |
| Kirk Ways | |
| Percival Barretto-Ko | Independent |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +6.0% |
| Q2 2026 | Aug 12, 2026 · Before open | +1.4% |
| Q1 2026 | May 13, 2026 · Before open | +1.6% |
| Q4 2025 | Mar 9, 2026 | +12.4% |
| Q3 2025 | Nov 10, 2025 · After close | −2.5% |
| Q2 2025 | Aug 14, 2025 · After close | +3.0% |
| Q1 2025 | Apr 15, 2025 · Before open | −58.0% |
| Q4 2024 | Mar 12, 2025 | −4.8% |
| Q3 2024 | Nov 12, 2024 · Before open | −1.3% |
| Q2 2024 | Aug 12, 2024 · After close | +3.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | +2.5% |
| Q4 2023 | Mar 13, 2024 · After close | −84.4% |
| Q3 2023 | Nov 13, 2023 · After close | −3.7% |
| Q2 2023 | Aug 14, 2023 · After close | −1.4% |
| Q1 2023 | May 15, 2023 · Before open | −2.2% |
| Q4 2022 | Mar 16, 2023 · After close | +1.3% |
| Q3 2022 | Nov 10, 2022 · After close | +10.5% |
| Q2 2022 | Aug 10, 2022 · After close | +3.6% |
| Q1 2022 | May 11, 2022 · After close | +1.6% |
| Q4 2021 | Mar 14, 2022 · After close | −1.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 22 slides | Aug 12, 2026 |
| Corporate Update (April 2025) | Corporate update | 15 slides | Apr 15, 2025 |
| Baird 2021 Global Healthcare Conference | Conference | 17 slides | Sep 15, 2021 |
| Investor Day (August 2021) | Investor day | 68 slides | Aug 25, 2021 |
Financings
| Raise | Date |
|---|---|
| Strategic investment Announced: US$5.5M Buyers: Cure Sanfilippo Foundation (part of a combined $5.5 million strategic investment); National MPS Society (part of a combined $5.5 million strategic investment) Use of proceeds: Partially fund the TA-ERT Expanded Access Program to broaden patient access to TA-ERT for Sanfilippo Syndrome Type B | Aug 12, 2026 |
| Public offering of common stock or pre-funded warrants Announced: Leerink Partners +4 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co. (co-lead), Jones, Craig-Hallum | Apr 20, 2026 |
| Private placement of common stock and pre-funded warrants Announced: about US$50M · US$68 a share · Leerink Partners +3 Dealers: Leerink Partners, Citizens Capital Markets, H.C. Wainwright & Co., Oppenheimer & Co. Use of proceeds: Advance tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B through a BLA submission in Q1 2026 and potential U.S. launch in late 2026 | Oct 8, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Oct 8, 2020.
- Price
- US$15.00 a share
- Shares offered
- 6,000,000 shares of common stock
- Offering size
- US$90 million
- Underwriters' option
- Up to 900,000 more shares
- Underwriters
- Cowen, SVB Leerink, Credit Suisse, RBC Capital Markets · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 7, 2020 |
| Filed publicly | Sep 18, 2020 |
| Amended once | Oct 5, 2020 |
| Shares registered with an exchange | Oct 5, 2020 |
| Declared effective by the SEC | Oct 8, 2020 |
| Final prospectus, with the price | Oct 9, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 9, 2020 |
| EFFECT · Notice that a registration is effective | Oct 8, 2020 |
| S-1MEF · Registration of more shares for the same offering | Oct 8, 2020 |
| CORRESP · Letter to the SEC | Oct 6, 2020 |
| CORRESP · Letter to the SEC | Oct 6, 2020 |
| CERT · Exchange's certificate of listing | Oct 6, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 5, 2020 |
| S-1/A · Registration statement, amended | Oct 5, 2020 |
| CORRESP · Letter to the SEC | Sep 18, 2020 |
| CORRESP · Letter to the SEC | Sep 18, 2020 |
All 13 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Sep 18, 2020 |
| UPLOAD · Letter from the SEC | Sep 4, 2020 |
| DRS · Draft registration statement | Aug 7, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 9, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 4.91M | 10.1M | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 21.0K | 49.4M | 429.0K | 381.0K | 102.0K | 12.0K | 1.00K | |
| Gross profit | -21.0K | 4.91M | 10.1M | -429.0K | -381.0K | -102.0K | -12.0K | -1.00K |
| Research and development | 19.5M | 46.4M | 49.4M | 35.2M | 30.7M | 23.9M | 10.8M | 8.40M |
| Selling, general and administrative | 17.0M | 14.6M | 12.7M | 12.1M | 11.4M | 5.56M | 2.29M | 1.57M |
| Operating income | -36.5M | -56.2M | -52.0M | -47.3M | -42.1M | -29.4M | -13.1M | -9.97M |
| Depreciation and amortization | 21.0K | 46.0K | 70.0K | 74.0K | 68.0K | 36.0K | 12.0K | 1.00K |
| EBITDA | -36.5M | -56.1M | -51.9M | -47.2M | -42.0M | -29.4M | -13.1M | -9.97M |
| Interest expense | 90.0K | 307.0K | 483.0K | 420.0K | 345.0K | 323.0K | 65.0K | 0 |
| Income before tax | -39.0M | -53.0M | -47.9M | -46.2M | -42.3M | -29.5M | -13.1M | -9.86M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 114.0K |
| Net income | -39.0M | -53.0M | -47.9M | -46.2M | -42.3M | -29.5M | -13.1M | -9.86M |
| Earnings per share, basic | -50.83 | -96.40 | -1.24 | -1.96 | -1.81 | -4.93 | -17.12 | -496.00 |
| Earnings per share, diluted | -50.83 | -96.40 | -1.24 | -1.96 | -1.81 | -4.93 | -17.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 48.9M | 38.8M | 96.3M | 24.5M | 42.7M | 157.2M | 3.92M | 4.11M |
| Short-term investments | 0 | 54.6M | 46.2M | 0 | ||||
| Receivables | 0 | |||||||
| Current assets | 52.1M | 44.2M | 102.2M | 83.6M | 91.9M | 160.4M | 4.65M | 4.77M |
| Property, plant and equipment | 1.40M | 140.0K | 73.0K | |||||
| Total assets | 53.0M | 45.2M | 103.9M | 85.6M | 126.5M | 162.9M | 4.69M | 4.78M |
| Accounts payable | 943.0K | 1.29M | 3.33M | 1.43M | 2.82M | 3.63M | 1.88M | 2.30M |
| Current liabilities | 10.1M | 15.2M | 24.5M | 12.4M | 8.87M | 9.76M | 4.30M | 2.71M |
| Long-term debt | 0 | 124.0K | 1.72M | 3.29M | 4.88M | 1.92M | 3.19M | |
| Total debt | 0 | 1.84M | 3.71M | 5.64M | 4.88M | 4.48M | 4.45M | |
| Total liabilities | 10.5M | 16.4M | 27.4M | 17.2M | 15.1M | 13.5M | 7.52M | 22.6M |
| Shareholders' equity | 42.5M | 28.8M | 76.5M | 68.5M | 111.4M | 149.4M | -30.6M | -17.8M |
| Shares outstanding | 1.37M | 563.0K | 41.0M | 23.6M | 23.5M | 23.3M | 764.4K | 19.9K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -33.3M | -56.0M | -33.3M | -41.7M | -35.9M | -27.5M | -12.6M | -8.57M |
| Capital spending | 0 | 0 | -7.00K | -8.00K | -93.0K | -74.0K | -4.00K | -4.00K |
| Free cash flow | -33.3M | -56.0M | -33.3M | -41.7M | -36.0M | -27.6M | -12.6M | -8.57M |
| Cash from investing | 0 | 55.8M | 23.7M | -79.2M | -74.0K | -4.00K | -4.00K | |
| Cash from financing | 43.5M | -1.62M | 49.1M | -241.0K | 643.0K | 181.0M | 12.4M | 12.4M |
| Dividends paid | -169.0K | -423.0K | ||||||
| Share buybacks | 25.0K | 66.0K | -311.0K | -40.0K | 134.0K | 93.4M | ||
| Change in cash | 10.2M | -57.6M | 71.6M | -18.2M | -114.4M | 153.4M | -188.0K | -8.57M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 27, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 8-K · Current report | May 26, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 21, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Apr 20, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 9, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 9, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 9, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Mar 9, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 9, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 12, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Nov 28, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 28, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 24, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 24, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Oct 29, 2025 | Offer document | SEC |
| S-3 · Registration statement | Oct 29, 2025 | Offer document | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 17, 2025 | Management or board change | SEC |
| D | Oct 16, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 9, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 8, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 8, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 12, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 12, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 6, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 6, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 29, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Apr 15, 2025 | Offer document | SEC |
| 10-K · Annual report | Apr 15, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 15, 2025 | Results | SEC |
| 8-K · Current report | Apr 1, 2025 | Results | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 27, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Oct 28, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 23, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Jun 18, 2024 | Material contract | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 8-K · Current report | May 24, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 8-K · Current report | Apr 30, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 25, 2024 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 5, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 5, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 5, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 28, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Mar 28, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 20, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 18, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 18, 2024 | Annual report | SEC |
| 144 · Notice of proposed sale | Mar 14, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 13, 2024 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 30, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 30, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
This page holds 200 of 369 filings. Open Filings
Cap table
Built by 6ix from Spruce Biosciences, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 2,874,013
- Fully diluted
- 2,874,013
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,874,013 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 2,874,013 |
| Sep 30, 2026 | 2,874,013 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Michael Grey Other companies: OnKure Therapeutics, Inc. (Director · Since at least Apr 8, 2021); Mirum Pharmaceuticals, Inc. (Director · Since at least Jul 17, 2019); Horizon Pharma PLC (Director · Sep 29, 2011 – May 3, 2018 · Past); BioMarin Pharmaceutical Inc. (Director · Dec 14, 2006 – Mar 5, 2021 · Past); Achillion Pharmaceuticals Inc (Director · Oct 25, 2006 – Dec 18, 2009 · Past); Idm Pharma Inc (Director · Jun 14, 2006 – Dec 11, 2008 · Past); SGX Pharmaceuticals Inc (President & CEO, Director · Jan 31, 2006 – Aug 20, 2008 · Past) | Executive Chairman, Director · Since at least Oct 8, 2020 |
| Adrian Quartel Other companies: Zevra Therapeutics, Inc. (Chief Medical Officer · Since at least Dec 6, 2024); Acer Therapeutics Inc (Chief Medical Officer · Feb 21, 2022 – Mar 14, 2023 · Past) | Chief Medical Officer · Since at least Jul 27, 2026 |
| Bali Muralidhar Other companies: Exicure, Inc. (Director · Jun 2, 2021 – Jun 13, 2022 · Past); OnKure Therapeutics, Inc. (Director · Apr 8, 2021 – Jun 6, 2023 · Past) | Director · Since at least Oct 8, 2020 |
| Camilla V. Simpson Other companies: GRI Bio, Inc. (Director · Since at least Apr 21, 2023) | Director · Since at least Oct 8, 2020 |
| Moghrabi Dina Chaya Other companies: Imago Biosciences Inc (Director · Jul 15, 2021 – Jan 11, 2023 · Past) | Director · Oct 8, 2020 – May 25, 2022 · Past |
| Samir Gharib Other companies: Talon Therapeutics Inc (Controller, Direct. of Finance · Oct 17, 2011 – Jul 17, 2013 · Past) | President and Chief Financial Officer · Since at least Oct 8, 2020 |
| Tiba Aynechi Other companies: MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024) | Director · Since at least May 22, 2024 |
| Agnieszka Jurecka | Vice President, Medical Affairs · Since at least Jun 22, 2026 |
| Brian Walls | Vice President, Market Access · Since at least May 13, 2026 |
| Bruno Gagnon | Senior Vice President, Clinical Development Operations · Since at least May 13, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Dale Hooks | Chief Commercial Officer · Since at least Mar 9, 2026 |
| Dan Spiegelman | Independent · Since at least Nov 4, 2026 |
| Darren Johnson | Vice President, Commercial Operations · Since at least May 13, 2026 |
| Dash Reddy | Vice President, Pharmaceutical Development and Manufacturing · Since at least Nov 4, 2026 |
| Daven Mody | Senior Vice President, Regulatory and Quality · Since at least May 13, 2026 |
| Eric Jordan | Vice President, Marketing · Since at least Jun 15, 2026 |
| Javier Szwarcberg | CHIEF EXECUTIVE OFFICER, Director · Since at least Jun 30, 2026 |
| Jessica Cohen Pfeffer | Vice President, Clinical Development · Since at least Aug 3, 2026 |
| Jonas Hansson | Director · Oct 8, 2020 – Oct 14, 2020 · Past |
| Keli Walbert | Independent · Since at least Dec 15, 2025 |
| Kirk Ways | Director · Since at least Oct 8, 2026 |
| Percival Barretto-Ko | Independent · Since at least Nov 5, 2026 |
| Ralph William Charlton III | CHIEF MEDICAL OFFICER · Dec 14, 2023 – Dec 10, 2024 · Past |
| Saba Sile | Senior Vice President, Clinical Development · Since at least Oct 8, 2026 |
| Tina Gullotta | Vice President, Finance and Corporate Controller · Since at least Jun 15, 2026 |
Log in to ask 6ix AI your own questions about Spruce Biosciences, Inc.